GlassScriptPhysician profile
Jeremiah Bro
NPI 1104337781
$6,533.76
in general payments reported to CMS, 2019-2025
31 companies · $717 in 2025
The $717 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,465 · 2022: $1,608 · 2023: $1,459 · 2024: $1,285 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,255.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $769.60 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $692.82 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $641.17 | 2021-2024 | |
| Abbott Laboratories | $570.97 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Amplatzer Amulet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.29 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $395.72 | 2021-2025 | Farxiga |
| Amarin Pharma, INC. | $184.75 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.88 | 2021-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $157.82 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $151.52 | 2022-2025 | Camzyos, Eliquis |
| Kestra Medical Technology Services, INC. | $145.31 | 2022-2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $116.83 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $108.47 | 2021-2025 | |
| Abiomed | $103.89 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $102.97 | 2022-2024 | Watchman Flx |
| Novo Nordisk INC | $91.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Actelion Pharmaceuticals US, INC. | $60.27 | 2021-2023 | Opsumit |
| Esperion Therapeutics, INC. | $59.27 | 2021 | |
| Alnylam Pharmaceuticals INC. | $55.10 | 2023-2025 | Onpattro |
| Amgen INC. | $46.99 | 2021-2024 | Repatha |
| Surmodics, INC. | $21.19 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| United Therapeutics Corporation | $19.58 | 2025 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $18.15 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $17.80 | 2024 | Injectafer |
| Scpharmaceuticals INC. | $17.12 | 2024 | |
| Edwards Lifesciences Corporation | $16.36 | 2022 | |
| Siemens Medical Solutions USA, INC. | $15.72 | 2025 | Acuson Origin Diagnostic Ultrasound System |
| Amryt Pharma Holdings LTD | $14.75 | 2021 | |
| Medtronic, INC. | $14.28 | 2023 | Linq II |
| Chiesi USA, INC. | $12.71 | 2023 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Bro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.